Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes: UKPDS 76.

Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes: UKPDS 76.

AIMS/HYPOTHESIS: Identification of variants predicting development of renal dysfunction would offer substantial clinical benefits. There is evidence that coding non-synonymous variants in the gene encoding paraoxonase 2 (PON2) are associated with nephropathy in both type 1 and type 2 diabetes. METHO...

Full description

Bibliographic Details
Main Authors:	Calle, R, McCarthy, M, Banerjee, P, Zeggini, E, Cull, C, Thorne, K, Wiltshire, S, Terra, S, Meyer, D, Richmond, J, Mancuso, J, Milos, P, Fryburg, D, Holman, R
Format:	Journal article
Language:	English
Published:	2006

Similar Items

Discordance in the paraoxonase (Pon1)-192QR polymorphism
by: Poh, R., et al.
Published: (2008)

Risk factors for incident albuminuria and renal dysfunction in the UKPDS
by: Adler, A, et al.
Published: (2000)

Paraoxonase-1 (PON1) activity in serum and various anticoagulated-plasma
by: Abdullah, Nor Zamzila, et al.
Published: (2012)

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.
by: Retnakaran, R, et al.
Published: (2006)

Hypoglycaemia in patients with Type 2 diabetes in the UKPDS
by: Cull, C, et al.
Published: (2001)

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
by: Cull, C, et al.
Published: (2004)

Paraoxonase (PON1) activities and lipid profiles among organophosphates (OPs) pesticide exposed workers
by: Ishaka, Aminu, et al.
Published: (2010)

A Study of Paraoxonase (PON-1) Activity and Concentration in Coronary Artery Disease Patients in Kuantan, Pahang
by: Abdullah, Nor Zamzila, et al.
Published: (2013)

A preliminary report on early Atherosclerostic changes and Paraoxonase(PON1) activity in Organophosphate exposed rats
by: M.Z., Zamzuria, et al.
Published: (2012)

UKPDS - 6-YEAR TRIAL OF SULFONYLUREA, INSULIN AND METFORMIN THERAPY IN TYPE-2 DIABETIC-PATIENTS WITH DIET FAILURE
by: Cull, C, et al.
Published: (1995)

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
by: Cull, C, et al.
Published: (2000)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
by: Turner, R, et al.
Published: (1999)

UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
by: Wright, A, et al.
Published: (1998)

Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90)
by: Leal, J, et al.
Published: (2021)

Framingham equations underestimate cardiovascular risk compared with the UKPDS risk engine in people with Type 2 diabetes
by: Price, H, et al.
Published: (2007)

Plasma lipids and hypoglycaemic therapies over 6 years in Type 2 diabetic patients in the UKPDS
by: Cull, C, et al.
Published: (1999)

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
by: Adler, A, et al.
Published: (2003)

An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).
by: Gray, A, et al.
Published: (2001)

Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).
by: Kohner, E, et al.
Published: (2001)

IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71).
by: Bottazzo, G, et al.
Published: (2005)

Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation
by: Coleman, R, et al.
Published: (2005)

Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.
by: Wright, A, et al.
Published: (2006)

Paraoxonase polymorphism MET-LEU 54 is associated with fatal myocardial infarction in type 2 diabetic patients
by: Groves, C, et al.
Published: (1998)

Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).
by: Davis, T, et al.
Published: (2005)

Ethnic differences in diabetic nephropathy - The UKPDS
by: Stevens, R, et al.
Published: (1999)

Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
by: Davis, T, et al.
Published: (2001)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49)
by: Turner, R, et al.
Published: (1999)

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
by: Stratton, I, et al.
Published: (2000)

Paraoxonase 1 activity as a predictor of cardiovascular disease in type 2 diabetes
by: Poh, R., et al.
Published: (2010)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
by: Matthews, DR, et al.
Published: (1998)

Glucose control in UKPDS type 2 diabetic patients with and without autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase.
by: Mehta, Z, et al.
Published: (1999)

Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).
by: Stratton, I, et al.
Published: (2006)

Plasma homocysteine, type 2 diabetes and risk of coronary heart disease in the UKPDS
by: Holman, R, et al.
Published: (2001)

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
by: Wright, A, et al.
Published: (2002)

Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)
by: Manley, SE, et al.
Published: (2000)

IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71) (vol 48, pg 703, 2005)
by: Bottazzo, G, et al.
Published: (2005)

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.
by: Adler, A, et al.
Published: (2000)

Performance and cost comparisons for A-PON and S-PON FTTH systems
by: Derahman, Mohd Noor, et al.
Published: (2007)

Performance and cost comparisons for A-PON and S-PON FTTH systems
by: Derahman, Mohd Noor, et al.
Published: (2007)

UKPDS: Plasma leptin, obesity and plasma insulin in type 2 diabetic subjects
by: Widjaja, A, et al.
Published: (1996)